Scarica l'app Stockscreener
6.56
2.50%
0.16
Dopo l'orario di chiusura:
6.56
Apollomics Inc Borsa (APLM) Ultime notizie
New Age Metals (OTCMKTS:NMTLF) Trading 1.2% Higher – Here’s Why - Defense World
Short Interest in Apollomics, Inc. (NASDAQ:APLMW) Decreases By 87.9% - Defense World
Orca Energy Group (OTCMKTS:ORXGF) Trading 1.4% Higher – What’s Next? - Defense World
(APLM) Long Term Investment Analysis - news.stocktradersdaily.com
Short Interest in Apollomics, Inc. (NASDAQ:APLMW) Increases By 75.8% - Defense World
How the (APLM) price action is used to our Advantage - news.stocktradersdaily.com
Apollomics (APLM) Trading Halted Due to Volatility | APLM Stock News - GuruFocus
Apollomics (APLM) Stock Trading Resumes | APLM Stock News - GuruFocus
(APLM) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Short Interest in Apollomics, Inc. (NASDAQ:APLMW) Decreases By 44.4% - Defense World
APLM stock touches 52-week low at $4.71 amid sharp annual decline By Investing.com - Investing.com South Africa
APLM stock touches 52-week low at $4.71 amid sharp annual decline - Investing.com Canada
(APLM) Investment Analysis - news.stocktradersdaily.com
APLM stock touches 52-week low at $6 amid market challenges - Investing.com Australia
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress - The Manila Times
Apollomics Achieves Major Clinical Win: 43% Response Rate Plus New $10M Partnership Deal Extends Runway - Stock Titan
Apollomics and LaunXP ink $50 M deal for NSCLC treatment in Asia - BioSpectrum Asia
Apollomics and LaunXP agree on NSCLC treatment in Asia - Yahoo
Apollomics, Inc. (NASDAQ:APLMW) Sees Significant Growth in Short Interest - Defense World
Apollomics, LaunXP enter development, commercial agreement for Vebreltinib - MSN
Apollomics Signs Exclusive Development, Commercialization Deal for Vebreltinib in Asia - MarketScreener
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib - GlobeNewswire
$60M Deal: Apollomics' Lung Cancer Drug Breakthrough Expands Across Asia - Stock Titan
Better Artificial Intelligence Stock: SoundHound AI vs. C3.ai - The Globe and Mail
Apollomics Inc. and LaunXP International Co., Ltd., Affiliate of LaunXP Biomedical Co., Ltd. Announce Development and Commercialization Agreement for Vebreltinib - marketscreener.com
Why Coinbase (COIN) Stock Is Trading Up Today - The Globe and Mail
Apollomics, Inc. (NASDAQ:APLMW) Short Interest Update - Defense World
These Were the 2 Top-Performing Stocks in the S&P 500 in February 2025 - The Globe and Mail
(APLM) Trading Advice - Stock Traders Daily
Apollomics, Inc. (NASDAQ:APLMW) Sees Large Decrease in Short Interest - Defense World
APLM Stock Hits 52-Week Low at $6.2 Amid Steep Yearly Decline - Investing.com Australia
APLM Stock Hits 52-Week Low at $6.2 Amid Steep Yearly Decline By Investing.com - Investing.com South Africa
GlycoMimetics ends key agreement; board members, executives depart - Investing.com
APLM stock touches 52-week low at $6.38 amid market challenges - MSN
APLM stock touches 52-week low at $6.38 amid market challenges By Investing.com - Investing.com South Africa
Objective long/short (APLM) Report - Stock Traders Daily
Apollomics, Inc. (NASDAQ:APLMW) Sees Significant Decrease in Short Interest - Defense World
Apollomics Shares Down in Premarket After Leukemia Drug Misses Phase-3 Targets - MarketWatch
Apollomics Announces Top-line Results for Phase 3 Bridging - GlobeNewswire
Apollomics, after giving up on GlycoMimetics' leukemia therapy, posts drug's latest phase 3 fail - Fierce Biotech
Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement - GlobeNewswire
APLM Stock Plummets to 52-Week Low, Hits $8.01 Amid Market Turbulence - Investing.com
Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split - GlobeNewswire
Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLMA Must-Watch This Week! - Marketscreener.com
Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024 - Yahoo Finance
Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance
Apollomics Inc.: Directors (Cayman Islands, 2024) - OffshoreAlert
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress - GlobeNewswire
Apollomics Announces Positive Preliminary Data of - GlobeNewswire
Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference - Yahoo Finance
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):